KIT
X2 Insulin Pump in the UK, Air Liquide
Healthcare's UK Diabetes Business
Manager Simon Treadwell says, "Since
launching the t:slim X2 in January of this year
we've welcomed a growing community of
new t:slim X2 pump users. We have a very
active UK-wide team of diabetes account
managers who are spending their time in
clinics, meeting with and training healthcare
professionals and patients on our products.
In just ten months, more than 1,000 people
have started using the t:slim X2, so it's been
a very busy first year for us. We're looking
forward to introducing the pump to more
people in 2020. The launch of Basal-IQ
Technology earlier this year has made a
huge difference to our community of pump
users who report reduced time spent in
hypoglycaemia and much improved time
in range. Basal-IQ is simple to learn and to
use, meaning patients are able to reap the
benefits of the technology as soon as they
switch on their pump."
Future proof
You may not have heard a lot about
Tandem, and even less about Air Liquide,
but we've done coverage of the t:slim
as well as both Basal- and Control-IQ,
primarily when looking at developments
coming out of America, where Tandem's
insulin pump has quite a footprint. It's now
time to give these companies, which both
have history with diabetes care in other
countries, another look.
Continues Treadwell, "Tandem Diabetes
Care are delivering new innovation to pump
users at a pace that is unprecedented in
this industry, and it's been an absolute
pleasure to represent this pioneering
product here in the UK. In recent months,
Tandem Diabetes Care have submitted the
algorithm for Control-IQ™ to the America
Federal Drugs Administration (FDA) for
approval. Control-IQ is an Advanced
Hybrid Closed Loop system that combines
*If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
** 2.0" x 3.13" x 0.6" (H x W x D) Weight•3.95 ounces (with a full 300-unit cartridge)
the t:slim X2 insulin pump, the Dexcom G6
CGM, and an algorithm built into the pump
that adjusts basal insulin delivery and gives
automatic correction boluses. While we
cannot yet commit to an exact launch date
for Control-IQ, we are looking forward to
making the technology available in the UK
in 2020."
All of us are vulnerable at some point in
our lives, when we are at greater risk due
to age or illness. Air Liquide Healthcare
states that its purpose is to protect lives
through innovative healthcare products,
services and support. It is committed to
ensuring that its customers receive the
very best and most cost-effective benefits
from its products and services. "In today's
competitive and constantly changing
markets," says Treadwell, "it is the added
value that we give our customers that
makes the vital difference."
For more information visit:
ADVERTORIAL
airliquidehealthcare.co.uk/tandem